drugset / Trial / NCT02098616
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
Completed
25 enrolled
Timothy Morgan, MD
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collabVA Long Beach Healthcare System · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.
Timeline
- Start
- 2014-07
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asunaprevir | Small molecule | 200 mg | Oral |
| Subject | Beclabuvir | Small molecule | 75 mg | Oral |
| Subject | Daclatasvir | Small molecule | 30 mg | Oral |
| Subject | Ribavirin | Small molecule | — | Oral |